Comparing Abpro (ABP) and The Competition

Abpro (NASDAQ:ABP) is one of 617 public companies in the “MED – BIOMED/GENE” industry, but how does it compare to its competitors? We will compare Abpro to similar businesses based on the strength of its valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.

Profitability

This table compares Abpro and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-241.16%
Abpro Competitors	-1,425.14%	-743.10%	-28.26%

Risk and Volatility

Abpro has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500. Comparatively, Abpro’s competitors have a beta of 0.99, suggesting that their average share price is 1% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Abpro and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1	1	0	0	1.50
Abpro Competitors	5605	12101	37483	1146	2.61

Abpro presently has a consensus price target of $120.00, suggesting a potential upside of 2,085.79%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 57.89%. Given Abpro’s higher possible upside, equities research analysts plainly believe Abpro is more favorable than its competitors.

Insider & Institutional Ownership

23.3% of Abpro shares are held by institutional investors. Comparatively, 51.2% of shares of all “MED – BIOMED/GENE” companies are held by institutional investors. 13.7% of Abpro shares are held by company insiders. Comparatively, 13.7% of shares of all “MED – BIOMED/GENE” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Abpro and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Abpro	$180,000.00	-$7.23 million	-2.29
Abpro Competitors	$960.92 million	-$46.52 million	11.59

Abpro’s competitors have higher revenue, but lower earnings than Abpro. Abpro is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Abpro competitors beat Abpro on 9 of the 13 factors compared.

Abpro Company Profile

Abpro Holdings Inc. is a biotechnology company. The company’s mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.